The lab’s first pub is a nifty piece of synth bio for genome editing the brain. Richardson et al. describe a platform to test and develop new high-precision genome editing reagents. Some of our new CRISPR fusions, like eRad18-Cas9-CtIP with linear donors, showed up to 45-times higher accuracy at point-mutation editing compared to vanilla CRISPR. Another step toward direct in vivo knockin and in situ gene therapy approaches!